Sensitivity analysis of parameters in linear-quadratic radiobiologic modeling.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 19306749.
- Also identified by DOI 10.1016/j.ijrobp.2008.11.039.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Radiobiologic modeling is increasingly used to estimate the effects of altered treatment plans, especially for dose escalation. The present article shows how much the linear-quadratic (LQ) (calculated biologically equivalent dose [BED] varies when individual parameters of the LQ formula are varied by +/-20% and by 1%. Equivalent total doses (EQD2 = normalized total doses (NTD) in 2-Gy fractions for tumor control, acute mucosal reactions, and late complications were calculated using the linear- quadratic formula with overall time: BED = nd (1 + d/ [alpha/beta]) - log(e)2 (T - Tk) / alphaTp, where BED is BED = total dose x relative effectiveness (RE = nd (1 + d/ [alpha/beta]). Each of the five biologic parameters in turn was altered by +/-10%, and the altered EQD2s tabulated; the difference was finally divided by 20. EQD2 or NTD is obtained by dividing BED by the RE for 2-Gy fractions, using the appropriate alpha/beta ratio. Variations in tumor and acute mucosal EQD ranged from 0.1% to 0.45% per 1% change in each parameter for conventional schedules, the largest variation being caused by overall time. Variations in "late" EQD were 0.4% to 0.6% per 1% change in the only biologic parameter, the alpha/beta ratio. For stereotactic body radiotherapy schedules, variations were larger, up to 0.6 to 0.9 for tumor and 1.6% to 1.9% for late, per 1% change in parameter. Robustness occurs similar to that of equivalent uniform dose (EUD), for the same reasons. Total dose, dose per fraction, and dose-rate cause their major effects, as well known.
Medical subject headings
- Algorithms
- Head and Neck Neoplasms
- Models, Biological
- Prostatic Neoplasms
- Relative Biological Effectiveness